|
|
Article: Reports summarize colon cancer research from Mayo Clinic.
- Article from:
- Cancer Weekly
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"Regulatory T cells (Tregs) express the forkhead box transcription factor (FoxP3) and suppress the antitumor immune response. We investigated whether the intratumoral densities of FoxP3(+) and effector CD3(+) lymphocytes are associated with prognosis of patients with colon cancer," investigators in the United States report (see also Colon Cancer).
"FoxP3 and CD3 expression and location were determined. in stage 11 and III colon carcinomas (n = 160) and normal mucosa (n = 25) by immunohistochemistry; CD4 and FoxP3 were localized by dual immunofluorescence microscopy. T-cell markers were compared with pathological variables, DNA mismatch repair status, and patient ...
Related newspaper, magazine, and journal articles:
|
|
Article: Studies from Mayo Clinic provide new data on ...
Cancer Weekly;
January 6, 2009 ;
700+ words
... ... States report (see also Colon Cancer Therapy). Human colorectal ... Okumura and colleagues, Mayo Clinic. The researchers concluded ... contact K. Okumura, Mayo Clinic, Miles and Shirley ... States, Rochester, Colon Cancer Therapy, Apoptosis ...
|
|